Next Article in Journal / Special Issue
HGF/Met-Signaling Contributes to Immune Regulation by Modulating Tolerogenic and Motogenic Properties of Dendritic Cells
Previous Article in Journal / Special Issue
Expression of Hepatocyte Growth Factor-Like Protein in Human Wound Tissue and Its Biological Functionality in Human Keratinocytes
Article

Anti-Differentiation Effect of Oncogenic Met Receptor in Terminally-Differentiated Myotubes

1
Department of Oncology, University of Turin, Corso Massimo D'Azeglio 52, 10126 Turin, Italy
2
Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126 Turin, Italy
3
Department of Oncology, Candiolo Cancer Institute—Fondazione del Piemonte per l'Oncologia (FPO) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Strada Provinciale 142, Km 3.95, 10060 Candiolo, Italy
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Zimmer Yitzhak
Biomedicines 2015, 3(1), 124-137; https://doi.org/10.3390/biomedicines3010124
Received: 23 December 2014 / Accepted: 4 February 2015 / Published: 12 February 2015
(This article belongs to the Special Issue New aspects of the Hepatocyte Growth Factor/c-Met System)
Activation of the hepatocyte growth factor/Met receptor is involved in muscle regeneration, through promotion of proliferation and inhibition of differentiation in myogenic stem cells (MSCs). We previously described that the specific expression of an oncogenic version of the Met receptor (Tpr–Met) in terminally-differentiated skeletal muscle causes muscle wasting in vivo. Here, we induced Tpr–Met in differentiated myotube cultures derived from the transgenic mouse. These cultures showed a reduced protein level of myosin heavy chain (MyHC), increased phosphorylation of Erk1,2 MAPK, the formation of giant sacs of myonuclei and the collapse of elongated myotubes. Treatment of the cultures with an inhibitor of the MAPK kinase pathway or with an inhibitor of the proteasome increased the expression levels of MyHC. In addition, the inhibition of the MAPK kinase pathway prevented the formation of myosacs and myotube collapse. Finally, we showed that induction of Tpr–Met in primary myotubes was unable to produce endoreplication in their nuclei. In conclusion, our data indicate that multinucleated, fused myotubes may be forced to disassemble their contractile apparatus by the Tpr–Met oncogenic factor, but they resist the stimulus toward the reactivation of the cell cycle. View Full-Text
Keywords: HGF; Met receptor; myogenic stem cells; skeletal muscle; differentiation; proteasome; Erk1,2 MAPK HGF; Met receptor; myogenic stem cells; skeletal muscle; differentiation; proteasome; Erk1,2 MAPK
Show Figures

Graphical abstract

MDPI and ACS Style

Sala, V.; Gallo, S.; Gatti, S.; Vigna, E.; Ponzetto, A.; Crepaldi, T. Anti-Differentiation Effect of Oncogenic Met Receptor in Terminally-Differentiated Myotubes. Biomedicines 2015, 3, 124-137. https://doi.org/10.3390/biomedicines3010124

AMA Style

Sala V, Gallo S, Gatti S, Vigna E, Ponzetto A, Crepaldi T. Anti-Differentiation Effect of Oncogenic Met Receptor in Terminally-Differentiated Myotubes. Biomedicines. 2015; 3(1):124-137. https://doi.org/10.3390/biomedicines3010124

Chicago/Turabian Style

Sala, Valentina, Simona Gallo, Stefano Gatti, Elisa Vigna, Antonio Ponzetto, and Tiziana Crepaldi. 2015. "Anti-Differentiation Effect of Oncogenic Met Receptor in Terminally-Differentiated Myotubes" Biomedicines 3, no. 1: 124-137. https://doi.org/10.3390/biomedicines3010124

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop